Kennett Sprogoe - 18 Mar 2026 Form 3 Insider Report for Ascendis Pharma A/S (ASND)

Reporting relationship
EVP & Head of Research & Product Development
Issuer ticker
ASND
Reported as of
18 Mar 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
18 Mar 2026, 18:09:41 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Michael Wolff Jensen as attorney-in-fact for Kennett Sprogoe

Key filing fact

Kennett Sprogoe filed Form 3 for Ascendis Pharma A/S (ASND) on 18 Mar 2026.

Key facts

  • This page summarizes Kennett Sprogoe's Form 3 filing for Ascendis Pharma A/S (ASND).
  • 0 reported transactions and 8 derivative rows are listed below.
  • Accepted by SEC: 18 Mar 2026, 18:09.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001965630 Primary reporting owner

SPROGOE KENNETT

Relationship
EVP & Head of Research & Product Development
Address
C/O ASCENDIS PHARMA A/S, TUBORG BOULEVARD 12, HELLERUP, DENMARK
Signature
/s/ Michael Wolff Jensen as attorney-in-fact for Kennett Sprogoe
Signature date
18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ASND holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
19,460
Date
18 Mar 2026
Ownership
Direct
Footnotes
F1
ASND holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
110
Date
18 Mar 2026
Ownership
By children
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ASND holding Derivative

Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
5,313
Exercise price
$37.18
Footnotes
F2
ASND holding Derivative

Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
45,000
Exercise price
$62.17
Footnotes
F2
ASND holding Derivative

Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
27,000
Exercise price
$108.00
Footnotes
F2
ASND holding Derivative

Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
22,755
Exercise price
$176.28
Footnotes
F2
ASND holding Derivative

Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
14,504
Exercise price
$139.65
Footnotes
F2
ASND holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
4,246
Exercise price
Footnotes
F3, F4
ASND holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
3,197
Exercise price
Footnotes
F4, F5
ASND holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
9,552
Exercise price
Footnotes
F4, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.

Footnote F2

The warrants are fully vested and currently exercisable.

Footnote F3

The restricted stock units vest on March 1, 2027 and have no expiration date.

Footnote F4

Each restricted stock unit represents a contingent right to receive one ADS.

Footnote F5

The restricted stock units vest in two equal annual installments beginning on March 1, 2027.

Footnote F6

The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

SEC remarks

EVP & Head of Research & Product Development

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .